Compare EU & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | ZVRA |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.7M | 499.9M |
| IPO Year | N/A | 2015 |
| Metric | EU | ZVRA |
|---|---|---|
| Price | $2.88 | $8.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $4.00 | ★ $21.71 |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | $44,142,000.00 | ★ $84,388,000.00 |
| Revenue This Year | $22.24 | $333.25 |
| Revenue Next Year | $86.15 | $43.70 |
| P/E Ratio | ★ N/A | $16.21 |
| Revenue Growth | N/A | ★ 244.60 |
| 52 Week Low | $1.01 | $6.19 |
| 52 Week High | $4.19 | $13.16 |
| Indicator | EU | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 43.59 |
| Support Level | $2.62 | $8.12 |
| Resistance Level | $2.75 | $8.80 |
| Average True Range (ATR) | 0.20 | 0.49 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 74.48 | 34.76 |
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.